Patents by Inventor Sue Cartlidge

Sue Cartlidge has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Targeted binding agents directed to PDGRF-alpha and uses thereof
    Patent number: 8697664
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: February 18, 2010
    Date of Patent: April 15, 2014
    Assignee: MedImmune Limited
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, Sue A. Cartlidge, David Charles Blakey
  • TARGETED BINDING AGENTS DIRECTED TO PDGRF-ALPHA AND USES THEREOF
    Publication number: 20110020360
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: February 18, 2010
    Publication date: January 27, 2011
    Applicant: ASTRAZENECA AB
    Inventors: NAOMI LAING, JASPAL SINGH KANG, IAN FOLTZ, GADI GAZIT-BOMSTEIN, XIAO-DANG YANG, SUE A. CARTLIDGE, DAVID CHARLES BLAKEY
  • Targeted binding agents directed to PDGFR-alpha and uses thereof
    Patent number: 7754859
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Grant
    Filed: August 3, 2007
    Date of Patent: July 13, 2010
    Assignee: AstraZeneca AB
    Inventors: Naomi Laing, Jaspal Singh Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Charles Blakey, Sue A. Cartlidge
  • TARGETED BINDING AGENTS DIRECTED TO PDGFR-ALPHA AND USES THEREOF
    Publication number: 20080089837
    Abstract: Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.
    Type: Application
    Filed: August 3, 2007
    Publication date: April 17, 2008
    Inventors: Naomi LAING, Jaspal Kang, Ian Foltz, Gadi Gazit-Bornstein, Xiao-Dang Yang, David Blakey, Sue Cartlidge
  • Use of an epitope of vascular endothelial growth factor receptor kdr/flk-1
    Publication number: 20050221317
    Abstract: The present invention relates to the use of the epitope which comprises the tyrosine at position 1214 in the amino acid sequencers the vascular endothelial growth factor receptor, KDR/Flk-1, as a marker in the measurement of a change in the activation state of the KDR/Flk-1 receptor and to probes, such as antibodies, which recognise said epitope. The invention also relates to the use of KDR/Flk-1 epitope Y1214 as a marker in the detection of and/or measurement of the level of the KDR/Flk-1 receptor and to assays which utilise the use of the Y1214 epitope and to compounds derived from said assays.
    Type: Application
    Filed: March 11, 2003
    Publication date: October 6, 2005
    Applicant: AstraZeneca AB
    Inventor: Sue Cartlidge